Latest news with #rezpegaldesleukin
Globe and Mail
11 hours ago
- Business
- Globe and Mail
Why Nektar Therapeutics Stock Was Red-Hot Today
The latest biotech stock to explode in price, Nektar Therapeutics (NASDAQ: NKTR) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after delivering excellent news from the lab, the company's shares leaped 19% higher on a significant analyst price target change. A clear buy, says analyst Well before market open, H.C. Wainwright's Arthur He poured some rocket fuel into his Nektar price target, setting it anew at $120 per share. That's far above his previous level, which was a mere $6.50. In making the change, he left his buy recommendation intact. In what's hardly a surprising development, He's adjustment was due to the positive results in the latest completed clinical trial for Nektar's eczema drug rezpegaldesleukin. The study put the medicine through its paces for the treatment of moderate-to-severe atopic dermatitis (AD), a form of eczema. In the analyst's view, it did well enough to become a top drug in the treatment of the affliction. On Tuesday, the biotech announced, no doubt with immense satisfaction, that rezpegaldesleukin met all of its primary and secondary endpoints in the phase 2b trial. After 16 weeks of treatment with the subcutaneous drug, patients demonstrated a 53% to 61% improvement in symptoms when measured with an eczema index. This compared very favorably to 31% for patients taking a placebo. Vast potential This easily makes Nektar's drug the success of the week in the biotech world. As pointed out by He, Rezpegaldesleukin clearly has potential to treat the many people who suffer from AD. As such, the progress of the drug -- and its developer -- will be exciting to watch going forward. Should you invest $1,000 in Nektar Therapeutics right now? Before you buy stock in Nektar Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nektar Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor 's total average return is809% — a market-crushing outperformance compared to175%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
Yahoo
11 hours ago
- Business
- Yahoo
Why Nektar Therapeutics Stock Was Red-Hot Today
An analyst tracking the stock made a drastic change to his price target. This closely followed good news from the lab for the company. 10 stocks we like better than Nektar Therapeutics › The latest biotech stock to explode in price, Nektar Therapeutics (NASDAQ: NKTR) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after delivering excellent news from the lab, the company's shares leaped 19% higher on a significant analyst price target change. Well before market open, H.C. Wainwright's Arthur He poured some rocket fuel into his Nektar price target, setting it anew at $120 per share. That's far above his previous level, which was a mere $6.50. In making the change, he left his buy recommendation intact. In what's hardly a surprising development, He's adjustment was due to the positive results in the latest completed clinical trial for Nektar's eczema drug rezpegaldesleukin. The study put the medicine through its paces for the treatment of moderate-to-severe atopic dermatitis (AD), a form of eczema. In the analyst's view, it did well enough to become a top drug in the treatment of the affliction. On Tuesday, the biotech announced, no doubt with immense satisfaction, that rezpegaldesleukin met all of its primary and secondary endpoints in the phase 2b trial. After 16 weeks of treatment with the subcutaneous drug, patients demonstrated a 53% to 61% improvement in symptoms when measured with an eczema index. This compared very favorably to 31% for patients taking a placebo. This easily makes Nektar's drug the success of the week in the biotech world. As pointed out by He, Rezpegaldesleukin clearly has potential to treat the many people who suffer from AD. As such, the progress of the drug -- and its developer -- will be exciting to watch going forward. Before you buy stock in Nektar Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nektar Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor's total average return is 809% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nektar Therapeutics Stock Was Red-Hot Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Business
- Yahoo
Wainwright sets over $100 target for Nektar on ‘paradigm-shifting' data
H.C. Wainwright analyst Arthur He raised the firm's price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares. The company this morning announced positive results from the induction period of its ongoing Phase 2b REZOLVE-AD study evaluating rezpegaldesleukin in patients with moderate to-severe atopic dermatitis, the analyst tells investors in a research note. Citing the drug's 'highly differentiated mechanism of action' compared to currently approved therapies, H.C. Wainwright believes rezpeg 'has the potential to reshape the treatment landscape' for atopic dermatitis. The firm expects to see further improvement in efficacy in the next clinical data update when the 36-week maintenance data is expected to be reported in Q1 of 2026. Nektar says a 'paradigm-shifting' atopic dermatitis drug 'has arrived.' The stock in midday trading is up 134%, or $12.82, to $22.36. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on NKTR: Disclaimer & DisclosureReport an Issue Nektar price target raised to $120 from $6.50 at H.C. Wainwright Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today? Nektar jumps 130% to $21.90 after atopic dermatitis study success Nektar Therapeutics Announces Positive Phase 2b Trial Results Nektar's rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
Nektar Therapeutics (NKTR) shares soared 12.1% in the last trading session to close at $9.54. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 13.2% loss over the past four weeks. The stock rallied as investor optimism grew over the company's review of top-line data from the phase IIb REZOLVE-AD study evaluating its pipeline candidate, rezpegaldesleukin, for treating moderate-to-severe atopic dermatitis. This biopharmaceutical company is expected to post quarterly loss of $2.53 per share in its upcoming report, which represents a year-over-year change of +32.5%. Revenues are expected to be $10.78 million, down 54.1% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. For Nektar, the consensus EPS estimate for the quarter has been revised 10.5% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on NKTR going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Nektar belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Indivior PLC (INDV), closed the last trading session 0.4% lower at $13.95. Over the past month, INDV has returned 24.4%. For Indivior, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.25. This represents a change of -43.2% from what the company reported a year ago. Indivior currently has a Zacks Rank of #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nektar Therapeutics (NKTR) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Graco Inc. (GGG) : Free Stock Analysis Report Stem, Inc. (STEM) : Free Stock Analysis Report Compugen Ltd. (CGEN) : Free Stock Analysis Report Modine Manufacturing Company (MOD) : Free Stock Analysis Report Liberty Media Corporation - Liberty Formula One Series A (FWONA) : Free Stock Analysis Report Sutro Biopharma, Inc. (STRO) : Free Stock Analysis Report Progyny, Inc. (PGNY) : Free Stock Analysis Report Indivior PLC (INDV) : Free Stock Analysis Report Cartesian Therapeutics, Inc. (RNAC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Forbes
2 days ago
- Business
- Forbes
Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?
Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, a biopharmaceutical ... More company located on 3rd Street, in the Mission Bay District of San Francisco, California, October 29, 2018. (Photo by Smith Collection/Gado/Getty Images) Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today's trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for treating moderate-to-severe atopic dermatitis (eczema), marking a pivotal moment for the cash-strapped biotech company. The study met both primary and secondary endpoints, validating the company's novel regulatory T-cell approach to treating inflammatory skin conditions. The Eczema Market Opportunity Atopic dermatitis represents a substantial market opportunity in the United States. Around 31.6 million people (roughly 10% of the population) have some form of eczema, according to the National Eczema Association. More than 30 million Americans live with atopic dermatitis--the skin condition commonly called eczema. While several FDA-approved treatments exist, including biologics like Dupixent, Ebglyss, Adbry, and Nemluvio, significant unmet medical need remains for patients who don't respond adequately to current therapies or experience side effects. The REZOLVE-AD Phase 2b study evaluated rezpegaldesleukin in 393 patients with moderate-to-severe atopic dermatitis. The study achieved its primary endpoint with improvements measured by the Eczema Area and Severity Index (EASI) score after a 16-week treatment period. The drug also met key secondary endpoints, including the proportion of patients achieving clear or almost clear skin. Financial Implications The positive results carry profound financial implications for Nektar, a company currently valued at just $250 million market capitalization. The company generates minimal revenue of approximately $87 million, derived mainly from royalty payments rather than product sales. If approved, rezpegaldesleukin could become a blockbuster treatment with peak sales projections exceeding $2 billion. This potential represents a dramatic transformation from Nektar's current royalty-dependent business model to a product-driven revenue structure. Acquisition Target Potential Nektar's successful Phase 2b results position the company as an attractive acquisition target for larger pharmaceutical companies seeking to expand their dermatology portfolios. The stark contrast between the company's current sub $300 million valuation and the multi-billion-dollar market potential for rezpegaldesleukin creates compelling acquisition economics. The stock's dramatic 100% single-day surge following the announcement reflects investor recognition of this treatment and the acquisition potential. Early-stage pharmaceutical companies with promising late-stage assets frequently become takeover targets, particularly when their market valuations appear disconnected from their pipeline potential. Investment Consideration Nektar represents a pure speculative play on future pipeline success and regulatory approval. The company's significant value proposition hinges on rezpegaldesleukin's ability to navigate remaining clinical hurdles and secure FDA approval. While the Phase 2b success significantly de-risks the program, investors must still contend with the inherent uncertainties of pharmaceutical development. While NKTR stock is on the rise, there always remains a meaningful risk when investing in a single, or just a handful of stocks. Consider Trefis High Quality (HQ) Portfolio which, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in HQ Portfolio performance metrics.
